Journal Information
Vol. 46. Issue S8.
EPOC: ¿cómo mejorar la atención al paciente?
Pages 15-19 (November 2010)
Share
Share
Download PDF
More article options
Vol. 46. Issue S8.
EPOC: ¿cómo mejorar la atención al paciente?
Pages 15-19 (November 2010)
Full text access
Parámetros de evaluación reportados por el paciente en la EPOC
Patient-reported parameters in chronic obstructive pulmonary disease
Visits
4599
Virginia Moya, David Nieto, José María Marín
Corresponding author
jmmarint@unizar.es

Autor para correspondencia.
Servicio de Neumología, Hospital Universitario Miguel Servet, Instituto Aragonés de Ciencias de la Salud, Zaragoza, España
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Resumen

La perspectiva que los pacientes con EPOC tienen de la enfermedad no coincide necesariamente con la del médico especialista. A este último le interesa principalmente evaluar y controlar el deterioro de la función pulmonar, ya que este aspecto define la presencia de la enfermedad y establece su gravedad. Sin embargo, al paciente lo que le preocupa son sus síntomas (sobre todo la disnea), su limitación para realizar actividades de la vida diaria y el deterioro progresivo de su calidad de vida. Estos aspectos se han denominado “parámetros reportados por el paciente” (PRP). En la clínica diaria, el médico sí se interesa por los PRP; sin embargo, los ensayos clínicos de nuevos fármacos o terapias para el tratamiento de la EPOC rara vez incluyen en su diseño la determinación de PRP como objetivos de eficacia. Esta praxis está cambiando con los últimos ensayos.

Palabras clave:
EPOC
Disnea
Calidad de vida
Capacidad de ejercicio
Parámetros relacionados con el paciente
Abstract

Patients’ and specialist physicians’ perspectives of chronic obstructive pulmonary disease (COPD) do not always coincide. Specialists are mainly interested in evaluating and monitoring pulmonary function deterioration, since this feature is the hallmark of the disease and indicates its severity. However, patients worry more about their symptoms (especially breathlessness), limitations for activities of daily living and progressive impairment of quality of life. These elements have been called “patient-reported parameters” (PRP). These parameters are of interest to physicians in daily clinical practice but clinical trials of new drugs or therapies for the treatment of COPD rarely include PRP determination in their design as measures of efficacy, although a change can be discerned in the latest trials.

Keywords:
COPD
Dyspnea
Quality of life
Exercise capacity
Patient-related parameters
Full text is only aviable in PDF
Bibliografía
[1.]
Food and Drug Administration. Guidance for industry: patient-reported outcome measures. Use in medical product development to support labeling claims: draft guidance. Rockville (MD): US Department of Health and Human Services; 2006.
[2.]
C. Laine, F. Davidoff.
Patient-cantered medicine: a professional evaluation.
JAMA, 275 (1996), pp. 152-156
[3.]
J.R. Curtis, D.P. Martin, T.M. Martin.
Patient-assessed health outcomes in chronic lung disease: what are they? How do they help us and where do we go from here.
Am J Respir Crir Care Med, 156 (1997), pp. 1032-1039
[4.]
M.D.L. Morgan, E. Threlfall, D. Sanders, I.M. Walden, M. Britton.
Living with COPD: results of the British Lung Fundaction survey.
Eur Repir J, 19 (2001), pp. 324
[5.]
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management of chronic obstructive pulmonary disease. NHLBI/WHO Report 2009. [Acceso Mayo 2010] Disponible en: www.goldcopd.com/workshop/index
[6.]
B.R. Celli, W. Macnee.
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.
Eur Respir J, 23 (2004), pp. 932-946
[7.]
D.J. Carlson, A.L. Ries, R.M. Kaplan.
Prediction of maximum exercise tolerance in patients with COPD.
Chest, 100 (1991), pp. 307-311
[8.]
D.E. O’Donnell, K.A. Webb.
Exertional breathlessness in patients with chronic airflow limitation: the role of lung hyperinflation.
Am Rev Respir Dis, 148 (1993), pp. 1351-1357
[9.]
O. Bauerle, C.A. Chrusch, M. Younes.
Mechanisms by which COPD affects exercise tolerance.
Am J Respir Crit Care Med, 157 (1998), pp. 57-68
[10.]
C. Fletcher, R. Peto.
The natural history of chronic airflow obstruction.
BMJ, 1 (1977), pp. 1645-1648
[11.]
N.R. Anthonisen, J.E. Connett, J.P. Kiley, M.D. Altose, W.C. Bailey, A.S. Buist, et al.
Effects of smoking intervention the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study.
JAMA, 272 (1994), pp. 1497-1505
[12.]
K. Nishimura, T. Izumi, M. Tsukino, T. Oga.
Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD.
Chest, 121 (2002), pp. 1434-1440
[13.]
B.R. Celli, C.G. Cote, J.M. Marin, C. Casanova, M. Montes de Oca, R. Mendez, et al.
The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.
N Engl J Med, 350 (2004), pp. 1005-1012
[14.]
D. Tashkin, S. Kesten.
Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses.
Chest, 123 (2003), pp. 1441-1449
[15.]
D.A. Mahler, D.H. Weinberg, C.K. Wells.
The measurement of dyspnea. Contents, interobserver agreement and physiologic correlates of two new clinical indexes.
Chest, 85 (1984), pp. 751-758
[16.]
D.E. O’Donnell, K.A. Webb.
Exertional breathlessness in patients with chronic airflow limitation: role of the lung hyperinsuflation.
Am Rev Respir Dis, 148 (1993), pp. 1351-1357
[17.]
J.M. Marin, S.J. Carrizo, M. Gascon, A. Sanchez, B. Gallego, B. Celli.
Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 163 (2001), pp. 1395-1399
[18.]
A. Domingo-Salvany, R. Lamarca, M. Ferrer, J. Garcia-Americh, J. Alonso, M. Felez, et al.
Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 166 (2002), pp. 680-685
[19.]
A. Ries, R. Kaplan, T. Limberg, L. Prewitt.
Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with COPD.
Ann Intern Med, 122 (1995), pp. 823-832
[20.]
C. Casanova, C. Cote, J. De Torres, A. Aguirre-Jaime, J.M. Marin, V. Pinto-Plata, et al.
Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive luna disease.
Am J Respir Crit Care Med, 171 (2005), pp. 591-597
[21.]
O. Bauerle, M. Younes.
Role of Ventilatory response to exercise in determining exercise capacity in COPD.
J Appl Physiol, 79 (1995), pp. 1870-1877
[22.]
D.A. Gerardi, L. Lovett, M.L. Benoit-Connors, J.Z. Reardon, R.L. ZuWallack.
Variables related to increased mortality following out-patient pulmonary rehabilitation.
Eur Respir J, 9 (1996), pp. 431-435
[23.]
L. Szekely, D. Oelberg, C. Wright, D. Johnson, J. Wain, B. Trotman-Dickenson, et al.
Preoperative predictors of operative mortality in COPD patients undergoing bilateral lung volume reduction surgery.
Chest, 111 (1997), pp. 550-558
[24.]
M. Sha, D. Hasselblad, M. Gheordiadis, S. Adams, K. Swedberg, R. Califf, et al.
Prognostic usefulness of the 6 minute walk in patients with advanced congestive heart failure secondary to ischemic and non-ischemic cardiomyopathy.
Am J Cardiol, 88 (2001), pp. 987-993
[25.]
S. Miyamoyo, N. Nagaya, T. Satoh, S. Kyotani, F. Sakamaki, M. Fujita, et al.
Clinical correlates and prognostic significance of 6 minute walk in patients with pulmonary hypertension. Comparison with cardiopulmonary exercise testing.
Am J Respir Crit Care Med, 161 (2000), pp. 487-492
[26.]
Pulmonary rehabilitation: official statement of the American Thoracic Society.
Am J Respir Crit Care Med, 159 (1999), pp. 1666-1682
[27.]
R. Güell, P. Casan, M. Sangenís, J. Santis, F. Morante, J.M. Borrás, et al.
Traducción española y validación de un cuestionario de calidad de vida en pacientes con enfermedad pulmonar obstructiva crónica.
Arch Bronconeumol, 31 (1995), pp. 202-210
[28.]
M. Ferrer, J. Alonso, L. Prieto.
Validity reliability of the St George's Respiratory Questionnaire after adaptation to a different language culture: the Spanish example.
Eur Respir J, 9 (1996), pp. 1160-1166
[29.]
P.M.A. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C. Jenkinns, P. Jones.
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
N Engl J Med, 356 (2007), pp. 775-789
[30.]
D.P. Tashkin, B. Celli, S. Senn, D. Bukhart, S. Kesten, S. Menjoge, et al.
A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
N Engl J Med, 359 (2008), pp. 1543-1554
[31.]
A.M. Schols, J. Slangen, L. Volovics, E.F. Wouters.
Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 157 (1998), pp. 1791-1797
[32.]
C. Casanova, C. Cote, J.M. Marin, V. Pinto-Plata, J.P. De Torres, A. Aguirre-Jaíme, et al.
Distance and Oxygen Desaturation During the 6-min Walk Test as Predictors of Long-term Mortality in Patients With COPD.
Chest, 134 (2008), pp. 753-760
[33.]
J.J. Soler-Cataluna, M.A. Martinez-Garcia, P. Roman, E. Salcedo, M. Navarro, R. Ochando.
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.
Thorax, 60 (2005), pp. 925-931
[34.]
D.A. Mahler, D. Tomlinson, E.M. Olmstead, A.N. Tosteson, G.T. O’Connor.
Changes in dyspnea, health status, and lung function in chronic airway disease.
Am J Respir Crit Care Med, 151 (1995), pp. 61-65
[35.]
R.A. Incalzi, L. Fuso, M. De Rosa, A. Di Napoli, S. Basso, G. Pagliari, et al.
Electrocardiographic signs of chronic cor pulmonale: a negative prognostic finding in chronic obstructive pulmonary disease.
Circulation, 99 (1999), pp. 1600-1605
[36.]
V.M. Pinto-Plata, C. Cote, H. Cabral, J. Taylor, B.R. Celli.
The 6-min walk distance: change over time value as a predictor of survival in severe COPD.
Eur Respir J, 23 (2004), pp. 28-33
[37.]
R.M. Kaplan, A.L. Ries, J. Reilly, Z. Mohsenifar.
Measurement of health related quality of life in the national emphysema treatment trial.
Chest, 126 (2004), pp. 781-789
[38.]
P.W. Jones, G. Harding, P. Berry, I. Wiklund, W.H. Chen, L.N. Kline.
Development first validation of the COPD Assessment Test.
Eur Respir J, 34 (2009), pp. 648-654
[39.]
R. Casaburi, D. Kukafka, C.B. Cooper, T.J. Witek, S. Keste.
Improvement in exercise tolerante with the combination of tiotropium and pulmonary rehabilitation in patients with COPD.
Chest, 127 (2005), pp. 809-817
[40.]
T. Welte, M. Miravitlles, P. Hernandez, G. Eriksson, S. Peterson, T. Polanowski, et al.
Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 180 (2009), pp. 741-750
[41.]
S.D. Aaron, K.L. Vandemheen, D. Ferguson, F. Maltais, J. Bourbeau, R. Goldstein, et al.
Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
Ann Intern Med, 146 (2007), pp. 545-555
[42.]
M. Cazzola, W. MacNee, F.J. Martinez, K.F. Rabe, L.G. Franciosi, P.J. Bernes, et al.
ATS/ERS Task Force Outcomes for COPD pharmacological trials: from lung function to biomarkers.
Eur Respir J, 31 (2008), pp. 461-468
[43.]
F.J. Martinez, M.K. Han, A.-C. Andrei, R. Wise, S. Murray, J.L. Curtis, et al.
Longitudinal change in the BODE index predicts mortality in severe emphysema.
Am J Respir Crit Care Med, 178 (2008), pp. 491-499
Copyright © 2010. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?